HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Speaker at Drug Delivery Events - Raja Chakraverty
Indian Council of Medical Research, India
Title : Nanoparticle mediated Drug Delivery system in Cerebrovascular disorders

Abstract:

In the realm of cerebrovascular incidents, the safeguarding of cerebral vasculature is recognized as a paramount goal. This talk will focus on the recent advances made in the domain of nanoparticle mediated drug delivery systems for cerebrovascular disorders. Worldwide in our efforts to ameliorate the central nervous system pathologies, a variety of free therapeutic agents including peptides, proteins, genetic material, and antisense oligonucleotides have been synthesized by research groups. Nevertheless, the therapeutic efficacy of a substantial number of these agents has been hindered by their undesirable characteristics upon in vivo administration. Factors such as suboptimal stability in biological fluids, swift enzymatic degradation, insufficient release kinetics, and adverse pharmacokinetic profiles contribute to the likelihood that these agents may fail to exhibit clinical effectiveness. To address these challenges, there is an increasing emphasis on the innovation of nanoscale carriers capable of protecting and targeting drug molecules that are otherwise ineffectual when administered in isolation. Such phenomena may catalyze the translocation of inflammatory cells towards the cerebral parenchyma, resulting in oxidative stress and edema, thereby provoking a secondary reperfusion injury downstream. Even in instances where thrombolysis is achieved, the consequences of reperfusion injury encompass an inflammatory cascade analogous to the alterations seen in ischemic tissue. In addition to the repercussions of reperfusion injury, the hemorrhagic transformation associated with ischemic stroke represents another potential early outcome, which may occur either spontaneously or after the application of recanalization therapy. In these contexts, the subsequent pathophysiological mechanisms intersect with those observed in parenchymal hemorrhagic stroke. Consequently, the urgent necessity lies in the advancement of a robust combination therapy for stroke, one that not only enhances thrombolytic activity but also alleviates the ramifications of secondary ischemia or reperfusion injury.

Biography:

Dr. Raja Chakraverty serves as an ICMR Scientist co-ordinating research on  Antimicrobial Resistance and based at the Department of Critical Care Medicine at IPGME&R, Kolkata. He is a well-known biomedical scientist who studied Pharmaceutical Technology at the UG, PG and Doctoral level. He has 11 years of rich teaching and research experience. Dr. Chakraverty has been awarded many accolades for Best Paper awards at National Seminars and has travelled to countries for academic discourses and invited orations. Dr. Chakraverty is a prolific writer who has published around 60 high impact articles in indexed journals and several book chapters and one book. Dr. Chakraverty is also a leading Editor for various journals. He is also a life member of the Indian Pharmacological Society.

Watsapp